Antipsychotic Drugs Market Forecast Highlights Expansion From $23.23 Billion To $33.25 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Antipsychotic Drugs Market Growth From $23.23 Billion In 2026 To $33.25 Billion By 2030 At A CAGR Of 9.4%
The market for antipsychotic medications has experienced notable expansion over recent years. Projected to rise from $21.25 billion in 2025 to $23.23 billion in 2026, this represents a compound annual growth rate (CAGR) of 9.3%. Several factors fueled this historical growth, including the launch of first-generation antipsychotics, heightened awareness surrounding mental health conditions, the development of hospital and clinical facilities, an increasing incidence of schizophrenia and bipolar disorder, and greater investment in research and development for neuropsychiatric drugs.
The market for antipsychotic drugs is projected to experience significant expansion over the coming years, climbing to $33.26 billion by 2030 with a compound annual growth rate (CAGR) of 9.4%. Key factors driving this forecast period growth include innovations in atypical and partial dopamine agonists, the growing use of precision medicine, the application of artificial intelligence in mental health diagnosis, the rise of online pharmacy channels, and an increased emphasis on long-acting injectable medications. Noteworthy trends shaping this period involve the shift toward personalized antipsychotic treatments, a growing elderly population, higher rates of schizophrenia and bipolar disorder, the emergence of telepsychiatry and digital mental health services, and the advancement of long-acting injectable antipsychotics.
Download A Free Sample Report For Comprehensive Market Insights:
Antipsychotic Drugs Market Expansion Supported By Key Demand Factors
The rising prevalence of mental health conditions is anticipated to boost the expansion of the antipsychotic drug market in the coming years. Mental disorders, also referred to as mental illnesses, are conditions that influence an individual’s thoughts, behaviors, mood, and overall psychological well-being. These cases can stem from factors such as stress levels, societal expectations, genetic predisposition, biochemical imbalances, neurodevelopmental issues, and physical health problems. Antipsychotic medications manage mental disorders by modulating neurotransmitter activity, specifically dopamine and serotonin, which helps alleviate psychotic symptoms, stabilize mood, and enhance cognitive and emotional functioning. For example, a November 2023 survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US public health agency, revealed that around 6% of adults aged 18 and older—approximately 15.4 million people—reported having a serious mental illness (SMI). Meanwhile, in September 2024, the Australian Institute of Health and Welfare, an Australian government agency, projected that the number of individuals living with dementia in Australia will rise from roughly 411,100 in 2023 to 849,300 by 2058, affecting about 315,500 men and 533,800 women. Consequently, the escalating occurrence of mental disorders is fueling growth in the antipsychotic drug market.
Antipsychotic Drugs Market Segment Analysis: What Are The Major Market Categories?
The antipsychotic drugs market covered in this report is segmented –
1) By Therapeutic Class: First Generation, Second Generation, Third Generation
2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies
Subsegments:
1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines
2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone
3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine
Antipsychotic Drugs Market Growth Trends Influencing Competitive Dynamics
Key players in the antipsychotic drug market are concentrating on the creation of cutting-edge medical solutions, including subcutaneous atypical antipsychotic injections, which aim to boost patient adherence and provide superior effectiveness when compared with conventional oral treatments. These subcutaneous injections, administered under the skin, are psychiatric medications used to manage mental health conditions, sustain consistent drug levels in the bloodstream, and enhance control over symptoms. A notable example occurred in April 2023, when Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical firm, partnered with MedinCell SA, a French manufacturer of biological products and pharmaceutical formulations, to debut UZEDY, which received approval from the U.S. Food and Drug Administration (FDA). This extended-release injectable formulation of risperidone, designed as a long-acting subcutaneous shot, offers adaptable dosing every one or two months. UZEDY leverages MedinCell’s proprietary SteadyTeq technology, guaranteeing a gradual medication release that achieves therapeutic concentrations within 6 to 24 hours after administration. During clinical studies, UZEDY was found to lower the risk of schizophrenia relapse by up to 80% relative to a placebo. It is specifically aimed at overcoming compliance challenges often seen with oral antipsychotics, which frequently result in relapse.
Antipsychotic Drugs Market Leading Companies Driving Competitive Growth
Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc
Access The Complete Antipsychotic Drugs Market Report:
Antipsychotic Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
